12:00 AM
 | 
Sep 28, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Droxidopa: Additional Phase III data

Top-line data from the double-blind portion of the placebo-controlled, international Phase III Study 302 trial in 101 patients showed that droxidopa missed the primary endpoint of significantly improving dizziness or light-headedness at 2 weeks as measured by the OHSA scale vs. placebo (1.3 vs. 1.9 unit increase, p=0.51). Droxidopa did meet the secondary endpoints of significantly improving standing short time, standing long time and the composite orthostatic hypotension activities of daily living score. Droxidopa was well tolerated with no serious adverse events reported.

Data from the double-blind, U.S and Canadian Phase III...

Read the full 445 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >